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Abstract
Background: The purpose of this study was to identify trends in survival and chemotherapy use for individuals with small-
cell lung cancer (SCLC) in England using the National Lung Cancer Audit (NLCA).
Methods: We used data from the NLCA database to identify people with histologically proven SCLC from 2004–2011. We
calculated the median survival by stage and assessed whether patient characteristics changed over time. We also assessed
whether the proportion of patients with records of chemotherapy and/or radiotherapy changed over time.
Results: 18,513 patients were diagnosed with SCLC in our cohort. The median survival was 6 months for all patients, 1 year
for those with limited stage and 4 months for extensive stage. 69% received chemotherapy and this proportion changed
very slightly over time (test for trends p = 0.055). Age and performance status of patients remained stable over the study
period, but the proportion of patients staged increased (p-value,0.001), mainly because of improved data completeness.
There has been an increase in the proportion of patients that had a record of receiving both chemotherapy and
radiotherapy each year (from 19% to 40% in limited and from 9% to 21% in extensive stage from 2004 to 2011). Patients
who received chemotherapy with radiotherapy had better survival compared with any other treatment (HR 0.24, 95% CI
0.23–0.25).
Conclusion: Since 2004, when the NLCA was established, the proportion of patients with SCLC having chemotherapy has
remained static. We have found an upward trend in the proportion of patients receiving both chemotherapy and
radiotherapy which corresponded to a better survival in this group, but as it only applied for a small proportion of patients,
it was not enough to change the overall survival.
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Introduction
Small-cell lung cancer (SCLC) accounted for 20% of all lung
cancer cases diagnosed over a decade ago [1] but this proportion
has decreased and currently only accounts for approximately 10%.
[2,3,4,5] SCLC is responsive to chemotherapy [6] (and combina-
tion chemo-radiotherapy) [7] and this is the main treatment
recommended by the National Institute of Health and Clinical
Excellence (NICE). [3] However, despite the sometimes dramatic
response to chemotherapy, many patients relapse and die within 6
months of diagnosis. [8] Furthermore, survival from SCLC is poor
in England compared with other European and North American
countries, [9,10,11] with only 5% of the patients surviving for at
least 5 years. [12].
The National Lung Cancer Audit (NLCA) was established in
2004 to measure the outcomes and quality of care for patients with
lung cancer provided by the National Health Services (NHS) and
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in doing so to improve the quality of the service. [13] The audit
has been used to set standards of care, such as 80% of patients
should be seen by lung cancer nurse specialists, 75% of patients
should have histological confirmation, and 95% patients should be
discussed by a multi-disciplinary team (MDT). These standards
are designed to make the treatment and care given in England
more comparable to other European and North American
countries. We used the NLCA database linked with the Hospital
Episode Statistic (HES) database to assess the impact of NLCA on
the English lung cancer population by studying the trends in
chemotherapy use, survival and changing features of patients with
SCLC since the audits introduction in 2004.
Methods
Data Source and Study Population
The NLCA database is a longitudinal database consisting of
anonymous computerised records of individuals with a diagnosis of
primary lung cancer. It has collected data on demographics,
tumour features and treatment since 2004 via 157 English NHS
hospitals responsible for managing and treating patients with lung
cancer. Data is usually entered by members of lung cancer MDT.
Using the NLCA database, we identified all English cases with
histologically proven SCLC diagnosed between 1st January 2004
and 31st December 2011. The NLCA dataset has been analysed
previously as part of a validation process [13], and currently the
case ascertainment is in excess of 90% [4,5]. We used linked data
from Hospital Episode Statistics (HES), a mandatory national
database collecting data on all in-patient diagnoses, consultant
referrals and treatment procedure performed, to provide addi-
tional information on co-morbidity and treatment and the Office
for National Statistics (ONS) which collects data from death
certificates, the registration of which is a legal requirement in the
United Kingdom (UK).
Covariates
For this study, we restricted our analyses to those patients with a
histologically proven diagnosis of SCLC based on the recorded
Systematised Nomenclature of Medicine (SNOMED) codes in the
NLCA database (M-8041/3). Our initial dataset included infor-
mation on age at diagnosis, sex, performance status (PS) and stage.
PS was classified according to the World Health Organisation
(WHO) definition and the stage was recorded using the Veteran’s
Administration Lung Study Group system (limited or extensive).
For a few cases where the most recent Tumour Node Metastases
staging system (TNM) was used, we converted this to limited (T1-
4, N0-3, M0) or extensive (M1a/b) as appropriate. [14] We
defined socio-economic status (SES) using the Townsend depriva-
tion Index, which uses a composite score of four variables
(unemployment, overcrowding, non-car ownership and non-home
ownership), and is split into 5 categories of deprivation. However
due to more than 90% of missing data on SES from 2004–2005,
we performed a separate analysis for 2006–2011.
To determine overall survival, we created a start date which was
the date of diagnosis. In the absence of a date of diagnosis, a
pseudo start date was generated using the median number of days
(for the whole cohort) between date of diagnosis and the following
dates in this order: (1) date first seen, (2) date of referral, or (3) date
discussed by MDT. An end date for each patient was created using
either the date of death (provided by ONS) or the date of the last
ONS cross-check for death dates (31st March 2013). Therefore
every patient had a minimum of 15 months of follow up for the
survival analysis.
Chemotherapy and Radiotherapy
We used the NLCA and HES dataset to determine whether an
individual in our cohort had received chemotherapy. From HES
in-patient hospital episodes for each patient, we used International
Classification of Diseases (ICD) codes Z51.1 & Z51.2 allocated for
‘chemotherapy session for neoplasm’ and ‘other chemotherapy’ to
indicate chemotherapy provision. We also identified Office of
Population Censuses and Survey Classification of Intervention
(OPCS-4) codes for chemotherapy from the HES database.
Presence of either one or both of the ICD/OPCS-4 codes from
the HES database was taken as evidence of receiving chemother-
apy. We also identified patients who had chemotherapy from the
NLCA database as HES does not record chemotherapy given
during an out-patient admission. Patients were classified as not
receiving chemotherapy if there was no date of chemotherapy in
the NLCA or HES. Patients were included in our study if their
date of diagnosis was in our study period. We excluded patients
from our cohort who had received their first dose of chemotherapy
1 month prior or 6 months after the date of diagnosis of lung
cancer. This step was done to minimise the skewing of overall
survival time in either direction by excluding patients who may
have received chemotherapy for some other cancer prior to being
diagnosed with SCLC or received chemotherapy for a slow
growing cancer which had been misclassified as SCLC (6 months
after date of diagnosis).
As the NLCA does not collect detailed information on
radiotherapy treatment type and intent, it is difficult to know
whether the radiotherapy was given for curative or palliative
purpose. However, we used the NLCA database to identify
patients who received radiotherapy using the date of radiotherapy
given. It was also difficult to identify patients who received
concurrent chemotherapy and radiotherapy as the NLCA records
only the first dose of either treatment. Only 404 patients (2%) had
clear evidence of concurrent chemotherapy and radiotherapy.
Statistical Analysis
All data management and statistical analyses were performed
using Stata version 12 (StataCorp, Texas). Initially, we calculated
the median age of diagnosis and median survival in days by the
year in which a patient was diagnosed with SCLC. The first two
years, 2004 and 2005, were grouped together to create a
comparator group of adequate size. We also looked at the patient
features at the time of diagnosis by year and performed the
Cuzick’s non-parametric test. A p-value of ,0.05 was considered
as significant. We also looked at the proportion of patients
receiving chemotherapy and the proportion who received both
chemotherapy and radiotherapy. We performed Cox regression
analysis to calculate the hazard ratios (HRs) depending on the type
of treatment received after the diagnosis compared with no
treatment received after diagnosis of SCLC, adjusted for patient
features and years.
Ethics
The data was obtained from the Heathcare Quality Improve-
ment Partnership (HQIP). Ethical approval from the University of
Nottingham medical school research ethnics committee was
obtained by the researchers to work on a linked HES and NLCA
dataset (RU943 177570-MV6J3). The NLCA has Ethics and
Confidentiality Committee (ECC) approval to use patient infor-
mation from the National Health Services (NHS). Finally for this
specific set of work, we also obtained approval from HQIP who
commission the audit and HSCIC caldicott guardian signed off the
data sharing agreement [IG Reference: IC381DS]. The data was
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anonymised in the linked dataset by the HSCIC personal prior to
be given to the researchers.
Results
There were a total of 178,427 individuals diagnosed with lung
cancer in the NLCA between 1st January 2004 and 31st December
2011. We restricted our analyses to only those individuals who had
a histologically proven SCLC (n= 18,513 (10.3%)). Table 1 shows
the patient features by year of diagnosis.
The median age at diagnosis remained the same at 69 years
(interquartile range (IQR) 62–75) from 2004–2011. A total of
12,811 (69.2%) patients received chemotherapy in our cohort and
this proportion had increased very slightly over the study period
showing a borderline significant trend (test for trends 0.055). Age
and PS did not change over the years. There was a significant
change in recording of stage (test for trends ,0.001), with a
decreasing proportion of patients with unknown, uncertain and
missing stage and increasing proportions of limited and extensive
stage SCLC. There was also a significant change in the
distribution of co-morbidity over the years, with more patients
having a Charlson index of 4 or more in more recent years (test for
trend across Charlson score groups p,0.001).
Table 2 represents the multivariate logistic regression analyses
for patients diagnosed between 2006 and 2011 (2004/2005
excluded because of high level of missing data on socioeconomic
status). The odds of receiving chemotherapy reduced with
increasing age, PS and co-morbidity (x2 p-value for trends ,
0.001). We also observed a significant association between
receiving chemotherapy and SES (ptrends,0.001), where patients
from least affluent areas were 13% less likely to receive
chemotherapy compared with patients from the most affluent
areas after adjusting for confounders (adjusted OR 0.87, 95% CI
0.77–0.99).
Chemotherapy and Radiotherapy
Table 3 shows the proportion of SCLC patients receiving
chemotherapy alone, radiotherapy alone and chemotherapy and
radiotherapy, stratified by stage. The proportion of patients who
received chemotherapy remained stable for all stages over the
years; however there was an increase in the proportion of patients
with recorded chemotherapy and radiotherapy for all stages. In
limited stage it increased from 19% to 40% and in extensive stage
from 10% to 21%. There was also an increase of recorded
chemotherapy and radiotherapy for unknown, uncertain and
missing stage. The use of radiotherapy alone, regardless of stage,
had also increased over the years. Patients who received chemo-
radiotherapy had a better median survival (335 days) compared
with chemotherapy alone (235 days), radiotherapy alone (82 days)
and no therapy (24 days) (data not shown). It was also observed
that patients who received chemo-radiotherapy were younger,
with less co-morbidity and had better PS compared with patients
who received chemotherapy or radiotherapy alone (table S1).
Survival
Median survival (MS) from the time of diagnosis for all the
patients (N= 18,513) was 6 months (IQR 1.5–12.4). This was 11.4
months (5.5–21.1) and 4 months (1.0–9.0) for patients with limited
and extensive stage disease (table 1). Kaplan-Meier survival curves
(Figure 1) also showed a difference in overall hazard ratios (HR)
based on the treatment received having adjusted for patient
features. Compared with patients who received no treatment
(MS=0.72 months), patients who received chemotherapy had an
adjusted HR of 0.33, 95% CI 0.32–0.34 (MS=7.6 months) and
patients who had records of radiotherapy and chemotherapy had
an adjusted HR of 0.24, 95% CI 0.23–0.25 (MS=11.6 months).
We also looked at the hazard ratios by limited and extensive stage
which showed a similar improved survival from receiving any
treatment compared with no treatment. However in limited stage
disease, there was only a small difference in survival for patients
receiving no treatment and those having radiotherapy alone.
Discussion
Principal Findings
Histologically proven SCLC accounted for 10% of the total
lung cancer cases diagnosed in the NLCA between 2004 and
2011. Survival in SCLC is poor and our results demonstrate that
the median survival has not changed in the 8 year period since the
audit began. The proportion of patients receiving chemotherapy
has increased very slightly over the years and although there has
been an increase in the proportion of patients receiving
chemotherapy and radiotherapy we observed no change in the
overall survival. One of the reasons for this could be the increase in
radiotherapy and chemo-radiotherapy observed in our study was
actually due to an increased use of prophylactic cranial irradiation
(PCI). This treatment is recommended in the NICE (2011)
updated guidelines [3], and has shown survival benefits in studies.
[15] However, it could not change our survival estimates as the
doubling proportion only accounted for a 20% increase in chemo-
radiotherapy from 2004–2011, which is still lower than other
comparable countries. In our study, there has been little change in
the patient demographics from 2004–2011. However, there has
been an increase in the proportions classified as extensive and
limited stage small-cell lung cancer and an increase in the
proportion of patients with more co-morbid illness, which may
lead to fewer patients being considered for curative treatment.
There was also inequality in chemotherapy use by socioeconomic
status where patients from least affluent areas were less likely to
receive chemotherapy.
Our results depict a low proportion of patients receiving chemo-
radiotherapy, especially for limited stage SCLC. However our
results are a reflection of the true treatment patterns and attitude
towards treatment in England. It should be noted that even
patients with limited stage SCLC can be considered too frail to
receive chemo-radiotherapy and in our cohort, one-third of the
limited stage SCLC patients had a PS of greater than or equal to 2
and almost the same proportion had a Charlson Index of greater
than or equal to 2.
Our results showed that patients who had recorded chemo-
therapy and radiotherapy had a longer median survival and lower
hazard ratio of death, which may reflect treatment efficiency or
selection bias such as immortal time bias. Immortal time bias here
refers to the fact that some patients, with an inherently better
prognosis would receive treatment whereas those with a poor
prognosis (associated with more advance disease and co-morbidity)
would not. The treatment may be having no effect on prognosis
and the apparent better survival may be simply a result of more
favourable biological factors.
Strengths and Limitations
The main strength of our study is the large sample size. As far as
we know, this is the largest study looking at the trends in
chemotherapy use and features of patients with SCLC in England
over the duration of the NLCA. Although the NLCA is non-
mandatory, it has been validated and found to be representative of
the population of lung cancer patients in England. [13] The
NLCA provides more data compared with databases used by other
Small-Cell Lung Cancer in England
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international studies (in which case-mix adjustment is not possible).
[9] Therefore we believe our results are likely to demonstrate real
changes in chemotherapy practice in England. The cases identified
in our study were all pathologically confirmed. Within the NLCA
missing or unknown pathology is coded as non-small cell lung
cancer. Thus some of these cases could have been small cell lung
cancer. It is unlikely that this is a significant proportion and most
unlikely that this would affect our conclusions. The proportion of
Table 1. Changing features of patients with small-cell lung cancer over the duration of the NLCA (n = 18,513).
Year of Diagnosis
2004/2005 2006 2007 2008 2009 2010 2011 test for trends
Number of patients N 1867 1836 2081 2697 3208 3325 3499
Median Survival in days
Whole cohort (n = 18513) 179 179 190 190 179 186 190
Limited stage (n = 4830) 358 321 343 362 332 358 339
Extensive stage (n = 9874) 102 120 139 124 113 124 124
Stage Unknown (n = 772) 168 135 183 219 128 223 256
Stage uncertain (n = 933) 226 208 208 194 237 201 285
Stage missing (2104) 168 164 164 161 142 142 168
Median age at diagnosis 67.9 68.2 68.3 68.1 68.3 68.6 68.7
Sex (%)
Female 879 (47.08) 843 (45.92) 926 (44.50) 1248 (46.27) 1537 (47.91) 1616 (48.60) 1741 (49.76)
Male 988 (52.92) 993 (54.08) 1155 (55.50) 1449 (53.73) 1671 (52.09) 1709 (51.40) 1758 (50.24) ,0.001
Age n (%)
,65 668 (35.78) 634 (34.33) 709 (34.07) 940 (34.85) 1105 (34.45) 1121 (33.71) 1144 (32.70)
65–75 607 (32.51) 612 (33.33) 710 (34.12) 901 (33.41) 1103 (34.38) 1124 (33.80) 1219 (34.84)
.75 592 (31.71) 590 (32.14) 662 (31.81) 856 (31.74) 1000 (31.17) 1080 (32.48) 1136 (32.47) 0.101{
Performance Status (%)
0 223 (11.94) 252 (13.73) 261 (12.54) 338 (12.53) 456 (14.21) 503 (15.13) 550 (15.72)
1 395 (21.16) 454 (24.73) 533 (25.61) 746 (27.66) 948 (29.55) 1039 (31.25) 1229 (35.12)
2 304 (16.28) 327 (17.81) 411 (19.75) 506 (18.76) 648 (20.20) 736 (22.14) 747 (21.35)
3 188 (10.07) 182 (9.91) 221 (10.62) 351 (13.01) 478 (14.90) 480 (14.44) 510 (14.58)
4 67 (3.59) 60 (3.27) 78 (3.75) 91 (3.37) 132 (4.11) 148 (4.45) 152 (4.34) 0.877{
missing 690 (36.96) 561 (30.56) 577 (27.73) 665 (24.66) 546 (17.02) 419 (12.60) 311 (8.89)
Charlson Index (%)
0 815 (43.65) 736 (40.09) 811 (38.97) 912 (33.82) 1035 (32.26) 954 (28.69) 948 (27.09)
1 321 (17.19) 344 (18.74) 383 (18.40) 486 (18.02) 581 (18.11) 595 (17.89) 603 (17.23)
2–3 191 (10.23) 218 (11.87) 238 (11.44) 346 (12.83) 415 (12.84) 436 (13.11) 471 (13.46)
4+ 540 (28.92) 538 (29.30) 649 (31.19) 953 (35.34) 1177 (36.69) 1340 (40.30) 1477 (42.21) ,0.001{
Stage (%)
SCLC-Limited 449 (24.05) 451 (24.56) 480 (23.07) 643 (23.84) 893 (27.84) 887 (26.68) 1027 (29.35)
SCLC-Extensive 794 (42.53) 824 (44.88) 951 (45.70) 1356 (50.28) 1693 (52.77) 2020 (60.75) 2236 (63.90)
SCLC-Unknown 177 (9.48) 246 (13.40) 156 (7.50) 90 (3.34) 62 (1.93) 24 (0.72) 17 (0.49)
SCLC-Uncertain 37 (1.98) 57 (3.10) 245 (11.77) 285 (10.57) 193 (6.02) 93 (2.80) 23 (0.66)
Stage missing 410 (21.96) 258 (14.05) 249 (11.97) 323 (11.98) 367 (11.44) 301 (9.05) 196 (5.60) ,0.001{
Chemotherapy n (%) 1236 (66.20) 1266 (68.95) 1483 (71.26) 1878 (69.63) 2188 (68.20) 2282 (68.63) 2478 (70.82) 0.055
Socio-economic status (%)
1 (Most Affluent) 234 (12.75) 314 (15.09) 395 (14.65) 494 (15.40) 458 (13.77) 487 (13.92)
2 312 (16.99) 383 (18.40) 469 (17.39) 582 (18.14) 600 (18.05) 657 (18.78)
3 348 (18.95) 413 (19.85) 546 (20.24) 620 (19.33) 615 (18.50) 716 (20.46)
4 381 (20.75) 455 (21.86) 575 (21.32) 738 (23.00) 711 (21.38) 789 (22.55)
5 (Least Affluent) 499 (27.18) 515 (24.75) 698 (25.88) 722 (24.06) 753 (22.65) 817 (23.35) 0.015{
Missing 62 (3.38) 1 (0.05) 14 (0.52) 2 (0.06) 188 (5.65) 33 (0.94)
{Cuzick’s non-parametric test for trends otherwise chi-square test for trends.
doi:10.1371/journal.pone.0089426.t001
Small-Cell Lung Cancer in England
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e89426
small-cell cases observed in our study is in accordance with a study
using the Thames Cancer Registry data. [2] A second limitation is
the high proportion of patients with stage missing, uncertain and
unknown, although this is decreasing year on year. We did not find
any evidence of a change in the ratio of limited to extensive stage
disease which suggests that the stage distribution did not change of
the years and therefore the comparisons of survival by stage over
the years was valid. It is unlikely that those patients with missing or
uncertain stage were misclassified because of poorer prognosis, as
we found their survival was better than those with extensive
disease.
We were able to validate records of chemotherapy by using a
combination of variables from NLCA and HES, but as inpatient
HES data does not capture the majority of radiotherapy episodes,
we might have underestimated the total proportion of patients who
had radiotherapy. In addition, due to the limited data on
radiotherapy, we were unable identify whether the radiotherapy
was given with curative or palliative intent.
We have shown an increase in the proportion of patients
receiving both chemotherapy and radiotherapy however our data
were unable to differentiate radical intent chemo-radiotherapy
from radiotherapy given for purely palliative purposes. Chemo-
radiotherapy is associated with fairly big survival benefits in
clinical trials and in our study there was some evidence of this.
However, our group receiving chemotherapy and radiotherapy
are likely to include a significant proportion of patients who had
both for palliative purposes and therefore any survival benefits of
chemo-radiotherapy would have been diluted. This probably
explains why the overall survival did not change with the increase
in the proportion of patients receiving chemotherapy and
radiotherapy.
Comparison with other Studies
We used a combination of databases and definitions to identify
patients who had received chemotherapy on an in-patient and out-
patient basis, and found that almost 70% of our cohort had
Table 2. Results for multivariate logistic regression analysis for patients diagnosed between 2006–2011 (n = 16,646).
Number of
patients n (%)
Proportion of patients
who received
chemotherapy n (%)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)` p-value
Sex
Female 7911 (48) 5533 (70) 1 1
Male 8735 (52) 6042 (69) 0.96 (0.90–1.03) 0.98 (0.91–1.06) 0.74{
Age
,65 5653 (34) 4670 (83) 1 1
65–75 5669 (34) 4170 (74) 0.58 (0.53–0.64) 0.64 (0.58–0.71)
.75 5324 (32) 2735 (51) 0.22 (0.20–0.24) 0.25 (0.23–0.28) ,0.001
Performance Status
0 2360 (14) 2107 (89) 1 1
1 4949 (30) 4220 (85) 0.69 (0.59–0.80) 0.88 (0.75–1.03)
2 3375 (20) 2289 (68) 0.25 (0.21–0.29) 0.39 (0.33–0.46)
3 2222 (13) 899 (40) 0.08 (0.06–0.09) 0.13 (0.11–0.15)
4 661 (4) 80 (12) 0.01 (0.01–0.02) 0.02 (0.02–0.03) ,0.001
missing 3079 (19) 1980 (64) 0.21 (0.18–0.25) 0.30 (0.25–0.35)
Stage
SCLC-Limited 4381 (26) 3522 (80) 1 1
SCLC-Extensive 9080 (55) 5952 (66) 0.46 (0.42–0.50) 0.67 (0.60–0.74)
SCLC-others 3185 (19) 2101 (66) 0.47 (0.42–0.52) 0.65 (0.58–0.74) ,0.001{
Charlson Index
0 5396 (32) 4363 (81) 1 1
1 2992 (18) 2211 (74) 0.67 (0.60–0.74) 0.81 (0.72–0.92)
2–3 2124 (13) 1432 (67) 0.48 (0.43–0.54) 0.67 (0.59–0.74)
4+ 6134 (37) 3569 (58) 0.32 (0.30–0.35) 0.50 (0.45–0.55) ,0.001
Socio-economic status
1 (Most affluent) 2382 (14) 1664 (70) 1 1
2 3003 (18) 2133 (71) 1.05 (0.94–1.19) 1.00 (0.87–1.15)
3 3258 (20) 2278 (70) 1.00 (0.89–1.12) 0.99 (0.86–1.13)
4 3649 (22) 2526 (69) 0.97 (0.86–1.08) 0.84 (0.74–0.96)
5 4054 (24) 2828 (70) 0.99 (0.89–1.11) 0.87 (0.77–0.99) 0.001
Missing 300 (2) 146 (49) 0.40 (0.32–0.52) 0.44 (0.33–0.59)
`Adjusted for all other variables in the table.
{Log-likelihood ratio p-value - otherwise x2 p-value.
doi:10.1371/journal.pone.0089426.t002
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received chemotherapy which was 10% higher than an earlier
study based on the NLCA database. [8] Previous studies including
one study conducted in the Netherlands [16] and one study using
the Surveillance Epidemiologic and End Results (SEERs) database
[17] showed survival improvement for patients with SCLC, which
we did not observe. However, the findings of the SEERs study of a
3% annual change in survival in both limited and extensive stage
SCLC were over a longer timeframe (1973–2002) than in the
present study. [17] Over this period treatment is likely to have
changed much more than from 2004 to 2011. Chemotherapy
regimens, supportive care and the use of combined chemo-
radiotherapy have changed to a greater extent based on evidence
from clinical trial in 1987 [18] and multiple meta-analysis in the
1990s [19,20] showing chemo-radiotherapy to have better
Table 3. Proportion of people receiving chemotherapy and radiotherapy by stage (n = 18513).
Year
Total patients
reported n (%)
Total patients with
recorded chemotherapy
n (%)
Patients with recorded
chemotherapy + radiotherapy n (%)
Recorded radiotherapy
only n (%)
Limited stage small-cell (n = 4830)
2004/2005 449 363 (80.85) 87 (19.38) 16 (3.56)
2006 451 356 (78.94) 50 (11.09) 15 (3.33)
2007 480 387 (80.63) 88 (18.33) 26 (5.42)
2008 643 501 (77.92) 172 (26.75) 37 (5.75)
2009 893 714 (79.96) 331 (37.07 52 (5.82)
2010 887 714 (80.50) 332 (37.43) 46 (5.19)
2011 1027 850 (82.77) 411 (40.02) 43 (4.19)
Extensive stage small-cell (n = 9874)
2004/2005 794 481 (60.58) 77 (9.70) 40 (5.04)
2006 824 548 (66.50) 69 (8.37) 43 (5.22)
2007 951 638 (67.09) 102 (10.73) 44 (4.63)
2008 1356 910 (67.11) 217 (16.00) 86 (6.34)
2009 1693 1068 (63.08) 292 (17.25) 139 (8.21)
2010 2020 1311 (64.90) 424 (20.99) 141 (6.98)
2011 2236 1477 (66.06) 474 (21.20) 129 (5.77)
Unknown stage small-cell (n =772)
2004/2005 177 108 (61.02) 22 (12.43) 11 (6.21)
2006 246 164 (66.67) 19 (7.72) 13 (5.28)
2007 156 111 (71.15) 28 (17.95) 4 (2.56)
2008 90 65 (72.22) 14 (15.56) 4 (4.44)
2009 62 42 (67.74) 15 (24.19) 5 (8.06)
2010 24 14 (58.33) 2 (8.33) 3 (12.50)
2011 17 12 (70.59) 4 (23.53) 0 (0.00)
Uncertain stage (n =922)
2004/2005 37 23 (62.16) 4 (10.81) 2 (5.41)
2006 57 36 (63.16) 5 (8.77) 1 (1.75)
2007 245 178 (72.65) 19 (7.76) 14 (5.71)
2008 285 190 (66.67) 62 (21.75) 22 (7.72)
2009 193 139 (72.02) 50 (25.91) 11 (5.70)
2010 93 62 (66.67) 20 (21.51) 6 (6.45)
2011 23 15 (65.22) 5 (21.74) 2 (8.70)
Stage missing (n =2104)
2004/2005 410 261 (63.66) 25 (6.10) 18 (4.39)
2006 258 162 (62.79) 17 (6.59) 12 (4.65)
2007 249 169 (67.87) 21 (8.43) 7 (2.81)
2008 323 212 (65.63) 50 (15.48) 20 (6.19)
2009 367 225 (61.31) 60 (16.35) 20 (5.45)
2010 301 181 (60.13) 58 (19.27) 22 (7.31)
2011 196 124 (63.40) 45 (22.96) 12 (6.12)
doi:10.1371/journal.pone.0089426.t003
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outcomes to chemotherapy alone promoting the use of newer
therapies. To our knowledge, there have been no new changes in
the treatment regimen of SCLC since 2004 and this is the likely
explanation for the lack of an annual overall survival improvement
in our study. Our study shows the inequality in chemotherapy use
in older patients (i.e. 65–75 & .75 years) even after adjusting for
several other patient features, which is similar to the results found
by other studies. [8,21,22] A similar association was seen in
patients from more deprived areas who were less likely to receive
chemotherapy, which is similar to the findings of other studies.
[8,23] We also observed that the proportion of patients with
comorbidities increased over the years, which is not seen in
previous studies. The reason for this is unknown but could be due
to better recording of comorbidities in the HES database.
Clinical Relevance
The overall survival of patients with SCLC has not changed
since the audit initiated in 2004, probably due to the fact that there
has been little change in the type of treatment offered or in the
stage at presentation. The only improvement we observed over the
years was an increase in the proportion of patients who received
radiotherapy in addition to chemotherapy which corresponded to
a better survival compared with other treatment regimens but as
this applied to only small proportion of the patients as a whole, it
was not enough to change the overall survival. The reasons for the
unchanged survival are unknown but this could be due to the
relatively modest advances in treatment for a small proportion of
patients (mostly chemo-radiotherapy for limited stage). It is
concerning that only a relatively small proportion of patients
receive chomo-radiotherapy, as this is the established best
standard of care, and clearly associated with better survival. The
therapy does not require patients to have a reasonable level of
fitness and co-morbidity rates in the UK can be high. Nevertheless
it is important for clinicians to reflect on our findings and to
consider whether more patients might be offered this apparently
more effective treatment.
The UK radiotherapy database and Systemic Anti-cancer
Therapy dataset (SACT) started to collect data in April 2009 and
April 2012, [24] and in due course, analysis of these data would
provide us with a more detailed picture of the impact of increasing
radiotherapy use on survival for patients with SCLC.
Supporting Information
Table S1 Baseline characteristics of patients receiving
chemo-radiotherapy, chemotherapy alone or radiother-
apy alone (n=18,513).
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